Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

OBJECTIVE: We aimed to evaluate the similarity of BAT2206 to its originator, ustekinumab, including pharmacokinetic profiles, immunogenicity, and safety in healthy Chinese male subjects. METHODS: This was a double-blinded, randomized, single-dose, parallel-group clinical trial, in which 270 healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Min, Li, Xiaojiao, Yang, Deming, Wang, Meng, Zhang, Hong, Li, Cuiyun, Mai, Jiajia, Yang, Lizhi, Qi, Yunpeng, Yu, Jin-Chen, Yang, Xiaolei, Wang, Zhaohe, Gu, Cailing, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684881/
https://www.ncbi.nlm.nih.gov/pubmed/36417156
http://dx.doi.org/10.1007/s40259-022-00563-5

Ejemplares similares

Ejemplares similares